05:37 PM EST, 11/14/2024 (MT Newswires) -- Gyre Therapeutics ( GYRE ) filed a shelf registration statement with the US Securities and Exchange Commission Thursday covering the potential sale of up to $150 million of its securities from time to time in one or more offerings.

The statement covers common and preferred shares, debt securities, warrants, and units.

The company said it will use the net proceeds generated from any securities sale for development, manufacturing, and scale-up, as well as for working capital and general corporate purposes, among other things.